celecoxib has been researched along with l 663536 in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Greiner, C; Koeberle, A; Schubert-Zsilavecz, M; Werz, O; Wurglics, M; Zettl, H | 1 |
| Dehm, F; Haberl, EM; Koeberle, A; Northoff, H; Pergola, C; Rossi, A; Sautebin, L; Troschuetz, R; Werz, O | 1 |
| Dittrich, M; Greiner, C; Hieke, M; Reisen, F; Schneider, G; Schubert-Zsilavecz, M; Werz, O | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Barz, D; Dehm, F; Hanke, T; Kaiser, A; Kunze, J; Lämmerhofer, M; Liening, S; Maczewsky, J; Pillong, M; Popella, SD; Sautebin, L; Schneider, G; Schubert-Zsilavecz, M; Weinigel, C; Werz, O; Wurglics, M | 1 |
| Jauch, J; Noha, SM; Paul, M; Schuster, D; Seitz, S; Verhoff, M; Werz, O | 1 |
| Hu, C; Ma, S | 1 |
| Bechi, P; Capaccioli, S; Cianchi, F; Cortesini, C; Fabbroni, V; Fanti, E; Lulli, M; Magnelli, L; Masini, E; Messerini, L; Papucci, L; Perigli, G; Perna, F; Schiavone, N; Vannacci, A | 1 |
| Lotan, R; Newman, RA; Schroeder, CP; Yang, P | 1 |
| Klein, T; Pushkareva, MA; Shephard, P; Sud'ina, GF | 1 |
| Ehrlich, K; Peskar, BA; Peskar, BM; Schuligoi, R | 1 |
| Ding, X; Qiang, H; Zhou, G; Zhou, X; Zhu, C | 1 |
| Arantes, EC; Bitencourt, Cda S; Bordon, Kde C; Faccioli, LH; Sampaio, SV; Sorgi, CA; Zoccal, KF | 1 |
| Arantes, EC; Faccioli, LH; Hori, JI; Paula-Silva, FW; Serezani, CH; Sorgi, CA; Zamboni, DS; Zoccal, KF | 1 |
| Chen, Z; Lin, H; Pan, B; Qiu, J; Tang, N; Tu, H; Wang, Z; Wu, X; Yao, Y; Yu, L; Zhang, X | 1 |
1 review(s) available for celecoxib and l 663536
| Article | Year |
|---|---|
Recent development of lipoxygenase inhibitors as anti-inflammatory agents.
Topics: | 2018 |
14 other study(ies) available for celecoxib and l 663536
| Article | Year |
|---|---|
Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase.
Topics: Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Cyclooxygenase 1; Cyclooxygenase 2; Drug Design; Enzyme Activation; Enzyme Inhibitors; Humans; Inflammation; Inhibitory Concentration 50; Intramolecular Oxidoreductases; Lipoxygenase Inhibitors; Models, Chemical; Prostaglandin-E Synthases; Pyrimidines | 2008 |
Discovery of benzo[g]indol-3-carboxylates as potent inhibitors of microsomal prostaglandin E(2) synthase-1.
Topics: Animals; Anti-Inflammatory Agents; Carboxylic Acids; Cell Line, Tumor; Edema; Enzyme Inhibitors; Humans; Indoles; Inhibitory Concentration 50; Intramolecular Oxidoreductases; Magnetic Resonance Spectroscopy; Male; Mice; Microsomes; Pleurisy; Prostaglandin-E Synthases; Rats; Rats, Wistar; Spectrometry, Mass, Electrospray Ionization | 2009 |
Discovery and biological evaluation of a novel class of dual microsomal prostaglandin E2 synthase-1/5-lipoxygenase inhibitors based on 2-[(4,6-diphenethoxypyrimidin-2-yl)thio]hexanoic acid.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Benzene Derivatives; Binding Sites; Caproates; Cells, Cultured; Cyclooxygenase Inhibitors; Humans; Intramolecular Oxidoreductases; Ligands; Lipoxygenase Inhibitors; Microsomes; Models, Molecular; Prostaglandin-E Synthases; Pyrimidines; Recombinant Proteins; Structure-Activity Relationship | 2011 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Aminothiazole-featured pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in vivo.
Topics: Animals; Arachidonate 5-Lipoxygenase; Binding Sites; Drug Design; Humans; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Intramolecular Oxidoreductases; Lipoxygenase Inhibitors; Male; Mice; Microsomes; Models, Molecular; Peritonitis; Prostaglandin-E Synthases; Protein Conformation; Pyrimidines; Structure-Activity Relationship; Thiazoles; Zymosan | 2013 |
Tetra- and pentacyclic triterpene acids from the ancient anti-inflammatory remedy frankincense as inhibitors of microsomal prostaglandin E(2) synthase-1.
Topics: Animals; Anti-Inflammatory Agents; Boswellia; Characidae; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Humans; Inhibitory Concentration 50; Intramolecular Oxidoreductases; Lipoxygenase Inhibitors; Molecular Structure; Pentacyclic Triterpenes; Prostaglandin Antagonists; Prostaglandin-E Synthases; Resins, Plant; Structure-Activity Relationship; Tetracycline; Triterpenes | 2014 |
Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells.
Topics: Aged; Animals; Antineoplastic Agents; Arachidonate 5-Lipoxygenase; bcl-2-Associated X Protein; Caco-2 Cells; Celecoxib; Cell Line; Cell Proliferation; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Female; HT29 Cells; Humans; Indoles; Lipoxygenase Inhibitors; Male; Membrane Proteins; Middle Aged; Pyrazoles; Receptors, Leukotriene; Sulfonamides | 2006 |
Simultaneous inhibition of COX-2 and 5-LOX activities augments growth arrest and death of premalignant and malignant human lung cell lines.
Topics: 5-Lipoxygenase-Activating Proteins; Apoptosis; Blotting, Western; Carrier Proteins; Celecoxib; Cell Cycle; Cell Death; Cell Division; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Dinoprostone; Humans; Hydroxyeicosatetraenoic Acids; Indoles; Leukotriene B4; Lipoxygenase Inhibitors; Lung Neoplasms; Membrane Proteins; Pyrazoles; Quinolines; Spectrometry, Mass, Electrospray Ionization; Sulfonamides | 2007 |
Cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) selectivity of COX inhibitors.
Topics: Arachidonate 5-Lipoxygenase; Arachidonic Acid; Blood; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Female; Humans; Indoles; Isoenzymes; Lipoxygenase Inhibitors; Molecular Structure; Neutrophils; Pyrazoles; Pyrroles; Random Allocation; Sulfonamides | 2008 |
Role of lipoxygenases and the lipoxin A(4)/annexin 1 receptor in ischemia-reperfusion-induced gastric mucosal damage in rats.
Topics: 16,16-Dimethylprostaglandin E2; Acetamides; Animals; Annexins; Anti-Ulcer Agents; Celecoxib; Cyclooxygenase Inhibitors; Dexamethasone; Drug Synergism; Flavanones; Fluorenes; Gastric Mucosa; Glucocorticoids; Indoles; Indomethacin; Lipoxygenase; Lipoxygenase Inhibitors; Male; Oligopeptides; Phenyl Ethers; Prostaglandin Antagonists; Pyrazoles; Rats; Rats, Wistar; Receptors, Formyl Peptide; Receptors, Lipoxin; Reperfusion Injury; Sulfonamides | 2009 |
Enhancing antitumor effects in pancreatic cancer cells by combined use of COX-2 and 5-LOX inhibitors.
Topics: Adenocarcinoma; Arachidonate 5-Lipoxygenase; Celecoxib; Cell Division; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Humans; Indoles; Lipoxygenase Inhibitors; MAP Kinase Signaling System; Molecular Targeted Therapy; Neoplasm Proteins; Pancreatic Neoplasms; Pyrazoles; Receptors, Leukotriene B4; Sulfonamides; Vascular Endothelial Growth Factor A | 2011 |
Ts6 and Ts2 from Tityus serrulatus venom induce inflammation by mechanisms dependent on lipid mediators and cytokine production.
Topics: Animals; Arachidonate 5-Lipoxygenase; Celecoxib; Cell Movement; Cyclooxygenase 2 Inhibitors; Cytokines; Immunohistochemistry; Indoles; Inflammation; Inflammation Mediators; Leukocytes; Leukotrienes; Lipids; Lipoxygenase Inhibitors; Male; Mice; Peritoneal Cavity; Prostaglandins; Pyrazoles; Scorpion Venoms; Sulfonamides | 2013 |
Opposing roles of LTB4 and PGE2 in regulating the inflammasome-dependent scorpion venom-induced mortality.
Topics: Animals; Arachidonate 5-Lipoxygenase; Blotting, Western; Carrier Proteins; Celecoxib; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclooxygenase Inhibitors; Dinoprostone; In Vitro Techniques; Indoles; Indomethacin; Inflammasomes; Interleukin-1beta; Leukotriene B4; Lipoxygenase Inhibitors; Macrophages; Macrophages, Peritoneal; Mice; Mice, Knockout; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Phosphoproteins; Prostaglandin Antagonists; Receptors, Prostaglandin E, EP2 Subtype; Receptors, Prostaglandin E, EP4 Subtype; Reverse Transcriptase Polymerase Chain Reaction; Scorpion Stings; Scorpion Venoms; Scorpions; Xanthones | 2016 |
2,5-dimethylcelecoxib alleviated NK and T-cell exhaustion in hepatocellular carcinoma via the gastrointestinal microbiota-AMPK-mTOR axis.
Topics: AMP-Activated Protein Kinases; Animals; Carcinoma, Hepatocellular; Celecoxib; Dinoprostone; Gastrointestinal Microbiome; Liver Neoplasms; Mice; T-Cell Exhaustion; Tumor Microenvironment | 2023 |